2-acylaminothiazoles for the treatment of cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9708279
SERIAL NO

14902319

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I):

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITE DE GENEVE24 RUE DU GÉNÉRAL-DUFOUR GENEVA 4 1211
UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCAMILANO (MI)
UNIVERSITE' CLAUDE BERNARD LYON 1BATIMENT 308 - C P E 43 BOULEVARD DU 11 NOVEMBRE 1918 VILLEURBANNE CEDEX 696222

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bisson, William Corvallis, US 3 1
D'Attoma, Joseph Villeurbanne, FR 1 0
Gambacorti-Passerini, Carlo Monza, IT 5 28
Goekjian, Peter Villeurbanne, FR 6 1
Mologni, Luca Vedano Al Lambro, IT 4 36
Scapozza, Leonardo Genève, CH 11 179

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 18, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 18, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00